Safe glycemic management during closed-loop treatment of type 1 diabetes: The role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia

Journal of Diabetes Science and Technology

Volumn 5, Issue 6, 2011, Pages 1373-1380

  Ward, W Kenneth ^a,b   Castle, Jessica R ^a   El Youssef, Joseph ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LEGACY RESEARCH   (United States)

Author keywords

Artificial pancreas; Glucagon; Glucose sensors; Insulin pump; Type 1 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON; INSULIN;

ALGORITHM; ARTIFICIAL PANCREAS; BLOOD; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MENTAL STRESS; METABOLISM; REVIEW;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GLUCAGON; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PANCREAS, ARTIFICIAL; STRESS, PSYCHOLOGICAL;

EID: 84862693536     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500608     Document Type: Conference Paper

References (32)

1. Nixon R and Pickup JC. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycemic control? Diabetes Technol Ther. 2011;13:93-8.
2. Anderbro T, Amsberg S, Adamson U, Bolinder J, Lins PE, Wredling R, Moberg E, Lisspers J, Johansson UB. Fear of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2010;27(10):1151-8. doi: 10.1111/j.1464-5491.2010.03078.x.
3. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60(5):469-76. (Pubitemid 41532446)
4. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43(3):396-402. (Pubitemid 24064246)
5. Castle JR, Engle JM, El Youssef J., Massoud RG, and Ward WK: Factors influencing the effectiveness of glucagon for preventing hypoglycemia. J Diabetes Sci Technol. 2010; 4: 1305-10.
6. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6):1282-7. Epub 2010 Mar 23.
7. Russell SJ, El-Khatib FH, Nathan DM, Damiano ER. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. J Diabetes Sci Technol. 2010;4(6):1288-304.
8. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27): 27ra27.
9. Kadish, A. Automation control of blood sugar a servomechanism for glucose monitoring and control. Trans Am Soc Artif Intern Organs. 1963;9:363-7.
10. Taborsky GJ Jr. The physiology of glucagon. J Diabetes Sci Technol. 2010;4(6): 1338-44.
11. Boyle PJ, Shah SD, Cryer, PE. Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting. Am J Physiol. 1989;256(5 Pt 1): E651-61.
12. Farhy, LS, McCall, AL. Models of glucagon secretion, their application to the analysis of the defects in glucagon counter-regulation and potential extension to approximate glucagon action. J Diabetes Sci Technol. 2010;4(6):1345-56.
13. Ward WK, Engle JM, Duman HM, Bergstrom C, Kim S, Federiuk IF. The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes. IEEE Sensors Journal. 2008;8:89-95.
14. El-Khatib, FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic Swine model in vivo. Diabetes Technol Ther. 2007;9:135-44. (Pubitemid 46652547)
15. Rivera N, Ramnanan CJ, An Z, Farmer T, Smith M, Farmer B, Irimia JM, Snead W, Lautz,M, Roach PJ, Cherrington AD. Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. J Clin Invest. 2010;120(12):4425-35. doi: 10.1172/JCI40919. Epub 2010 Nov 15.
16. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24(4):643-5. (Pubitemid 32888841)
17. Shulman GI, Rossetti L, Rothman DL, Blair JB, Smith D. Quantitative analysis of glycogen repletion by nuclear magnetic resonance spectroscopy in the conscious rat. J Clin Invest. 1987;80(2):387-93.
18. Ward WK, Massoud RG, Szybala CJ, Engle JM, El Youssef J, Carroll JM, Roberts CT, Jr, DiMarchi RD. In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect. J Diabetes Sci Technol. 2010;4(6):1311-21.
19. Steiner SS, Li M, Hauser R, Pohl R. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol. 2010;4(6):1332-7.
20. Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD. Optimization of the native glucagon sequence for medicinal purposes. J Diabetes Sci Technol. 2010;4(6):1322-31.
21. El Youssef J, Castle J, Ward W. A Review of Closed-Loop Algorithms for Glycemic Control in the Treatment of Type 1 Diabetes. Algorithms. 2009;2(1):518-32.
22. Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF. An implantable subcutaneous glucose sensor array in ketosis-prone rats: closed loop glycemic control. Artif Organs. 2005;29(2):131-43. (Pubitemid 41623718)
23. Gopakumaran B, Duman HM, Overholser DP, Federiuk IF, Quinn MJ, Wood MD, Ward WK. A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional-derivative method. Artif Organs. 2005;29(8):599-607. (Pubitemid 41602836)
24. Federiuk IF, Casey HM, Quinn MJ, Wood MD, Ward WK. Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment. Comp Med. 2004;54(3):252-7. (Pubitemid 38856984)
25. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Orsini Federici M, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25(4):905-20. (Pubitemid 39121173)
26. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68(6): 1456-67. (Pubitemid 12194400)
27. El Youssef J, Castle JR, Branigan DL, Massoud RG, Breen ME, Ward K. A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteriod-induced stress hypoglycemia in type 1 diabetes. J of Diabetes Sci Technol. 2011;(5(6):1312-26.
28. El Youssef J, Castle JR, Massoud RG, Branigan D, Ward WK. Automated Adaptive Closed Loop Insulin Delivery for Stress Hyperglycemia in Type 1 Diabetes. Proceedings of ADA Scientific Sessions, June 2011, San Diego. 2011.
29. Castle JR, El Youssef J, Massoud RG, Branigan D, Ward WK. The Benefit of Multiple Glucose Sensors in Type 1 Diabetes: Implications for Artificial Pancreas Design. Proceedings of ADA Scientific Sessions, June 2011, San Diego. 2011.
30. Ward WK, Troupe JE. Assessment of chronically implanted subcutaneous glucose sensors in dogs: the effect of surrounding fluid masses. ASAIO J. 1999;45(6):555-61. (Pubitemid 30017346)
31. Ward WK, Wood MD, Troupe JE. Understanding spontaneous output fluctuations of an amperometric glucose sensor: effect of inhalation anesthesia and use of a nonenzyme containing electrode. ASAIO J. 2000;46(5):540-6.
32. Ward WK, Wood MD, Troupe JE. Rise in background current over time in a subcutaneous glucose sensor in the rabbit: relevance to calibration and accuracy. Biosens Bioelectron. 2000;15(1-2):53-61. (Pubitemid 32667458)